Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 144

1.

[Methodological aspects of clinical and economic impact of vaccine interventions and HTA. Focus on HPV vaccination].

Ricciardi W, Dirodi B, Bonanni P, Capri S, Castiglia P, Gabutti G, Gasparini R, Giorgi Rossi P, Grilli G, La Torre G.

Ann Ig. 2011 Sep-Oct;23(5):419-34. Italian.

PMID:
22403995
2.

Clinical perspectives on the role of the human papillomavirus vaccine in the prevention of cancer.

Julius JM, Ramondeta L, Tipton KA, Lal LS, Schneider K, Smith JA.

Pharmacotherapy. 2011 Mar;31(3):280-97. doi: 10.1592/phco.31.3.280. Review.

PMID:
21361739
3.

Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.

Muñoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia PJ, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Huh WK, Joura EA, Kurman RJ, Majewski S, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Lupinacci LC, Giacoletti KE, Sings HL, James MK, Hesley TM, Barr E, Haupt RM.

J Natl Cancer Inst. 2010 Mar 3;102(5):325-39. doi: 10.1093/jnci/djp534. Epub 2010 Feb 5.

PMID:
20139221
4.

Cost-consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: the potential impact of different cross-protection profiles.

Capri S, Gasparini R, Panatto D, Demarteau N.

Gynecol Oncol. 2011 Jun 1;121(3):514-21. doi: 10.1016/j.ygyno.2011.01.029. Epub 2011 Feb 19.

PMID:
21334734
5.

[Cervical cancer screening: past--present--future].

Breitenecker G.

Pathologe. 2009 Dec;30 Suppl 2:128-35. doi: 10.1007/s00292-009-1189-1. German.

PMID:
19756616
6.

[Health technology assessment report: Computer-assisted Pap test for cervical cancer screening].

Della Palma P, Moresco L, Giorgi Rossi P.

Epidemiol Prev. 2012 Sep-Oct;36(5 Suppl 3):e1-43. Italian.

7.

Epidemiology of human papillomavirus infection and cervical cancer and future perspectives in Hong Kong, Singapore and Taiwan.

Tay SK, Ngan HY, Chu TY, Cheung AN, Tay EH.

Vaccine. 2008 Aug 19;26 Suppl 12:M60-70. doi: 10.1016/j.vaccine.2008.05.042.

PMID:
18945415
8.
9.

The Health Technology Assessment of bivalent HPV vaccine Cervarix in Italy.

La Torre G, de Waure C, Chiaradia G, Mannocci A, Capri S, Ricciardi W.

Vaccine. 2010 Apr 26;28(19):3379-84. doi: 10.1016/j.vaccine.2010.02.080. Epub 2010 Mar 1.

PMID:
20197141
10.

Promising strategies for cervical cancer screening in the post-human papillomavirus vaccination era.

Tota J, Mahmud SM, Ferenczy A, Coutlée F, Franco EL.

Sex Health. 2010 Sep;7(3):376-82. doi: 10.1071/SH10022. Review.

PMID:
20719230
11.

Economic evaluation of policy options for prevention and control of cervical cancer in Thailand.

Praditsitthikorn N, Teerawattananon Y, Tantivess S, Limwattananon S, Riewpaiboon A, Chichareon S, Ieumwananonthachai N, Tangcharoensathien V.

Pharmacoeconomics. 2011 Sep;29(9):781-806. doi: 10.2165/11586560-000000000-00000.

PMID:
21838332
12.

Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland.

Szucs TD, Largeron N, Dedes KJ, Rafia R, Bénard S.

Curr Med Res Opin. 2008 May;24(5):1473-83. doi: 10.1185/030079908X297826 . Epub 2008 Apr 14.

PMID:
18413014
13.

Harnessing the power of prevention: human papillomavirus vaccines.

Mayeaux EJ Jr.

Curr Opin Obstet Gynecol. 2006 Feb;18 Suppl 1:s15-21. Review.

PMID:
16520680
14.

A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program.

Kulasingam S, Connelly L, Conway E, Hocking JS, Myers E, Regan DG, Roder D, Ross J, Wain G.

Sex Health. 2007 Sep;4(3):165-75.

PMID:
17931529
15.

Monitoring the control of human papillomavirus (HPV) infection and related diseases in Australia: towards a national HPV surveillance strategy.

Brotherton JM, Kaldor JM, Garland SM.

Sex Health. 2010 Sep;7(3):310-9. doi: 10.1071/SH09137.

PMID:
20719220
16.

Cost-effectiveness analysis for Pap smear screening and human papillomavirus DNA testing and vaccination.

Chen MK, Hung HF, Duffy S, Yen AM, Chen HH.

J Eval Clin Pract. 2011 Dec;17(6):1050-8. doi: 10.1111/j.1365-2753.2010.01453.x. Epub 2011 Jun 16.

PMID:
21679279
17.

Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico.

Reynales-Shigematsu LM, Rodrigues ER, Lazcano-Ponce E.

Arch Med Res. 2009 Aug;40(6):503-13. doi: 10.1016/j.arcmed.2009.08.004.

PMID:
19853192
18.

Age for HPV vaccination.

Harper DM, Paavonen J.

Vaccine. 2008 Mar 14;26 Suppl 1:A7-11. Review.

PMID:
18642467
19.

Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening.

Adams M, Jasani B, Fiander A.

Vaccine. 2007 Apr 20;25(16):3007-13. Epub 2007 Jan 18. Review.

PMID:
17292517
20.

Efficacy and other milestones for human papillomavirus vaccine introduction.

Pagliusi SR, Teresa Aguado M.

Vaccine. 2004 Dec 16;23(5):569-78. Review.

PMID:
15630792

Supplemental Content

Support Center